Close Menu

Genetics & Genomics Business, Policy & Funding

Breaking news on Genetics & Genomics business, policy & funding.

Nuvisan, based in Waltrop, Germany, will use ERS'w Genomics CRISPR-Cas9 portfolio to help advance its clients' drug discovery and early development programs.

Both firms highlighted the company's proximity extension assay technology and its ability to provide highly multiplexed proteomic analyses.

The company is commercializing a test that combines genetic and hormone data with a woman's medical history to make personalized birth control recommendations.

The PCR test is designed to detect the N gene of the virus in a variety of healthcare provider-collected specimens including anterior nasal swabs.

Italy has held talks with vaccine developers to manufacture mRNA-based SARS-CoV-2 vaccines, according to the Financial Times.

The Associated Press reports US officials are removing restrictions on fetal tissue research that were added during the Trump Administration.

The Biden Administration is investing $1.7 billion to detect and monitor SARS-CoV-2 variants.

In PLOS this week: genome instability in Aicardi-Goutières Syndrome, introduction of SARS-CoV-2 to the Colombian Amazon, and more.